<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="pkd-ar" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">pkd-ar</book-part-id>
      <title-group>
        <title>Polycystic Kidney Disease, Autosomal Recessive</title>
        <alt-title alt-title-type="alt-title">Synonyms: ARPKD, ARPKD/CHF</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sweeney</surname>
            <given-names>William E</given-names>
          </name>
          <degrees>MS</degrees>
          <aff>Assistant Professor of Pediatrics<break/>Operations Manager, Children's Research Institute<break/>Medical College and Children's Health System of Wisconsin<break/>Milwaukee, Wisconsin</aff>
          <email>bsweeney@mcw.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Avner</surname>
            <given-names>Ellis D</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Emeritus Professor of Pediatrics and Physiology<break/>Director, Multidisciplinary Program for Childhood PKD<break/>Founding Associate Dean for Pediatric Research and Director of Children's Research Institute <break/>Medical College and Children's Health System of Wisconsin<break/>Milwaukee, Wisconsin</aff>
          <email>eavner33@gmail.com</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>19</day>
          <month>7</month>
          <year>2001</year>
        </date>
        <date date-type="updated">
          <day>15</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="revised">
          <day>14</day>
          <month>7</month>
          <year>2009</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="pkd-ad" document-type="chapter">Polycystic Kidney Disease, Autosomal Dominant</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="plosl" document-type="chapter">Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL)</related-object>
      <abstract id="pkd-ar.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Autosomal recessive polycystic kidney disease (ARPKD) belongs to a group of congenital hepatorenal fibrocystic syndromes and is a cause of significant renal and liver-related morbidity and mortality in children. The majority of individuals with ARPKD present in the neonatal period with enlarged echogenic kidneys. Renal disease is characterized by nephromegaly, hypertension, and varying degrees of renal dysfunction. More than 50% of affected individuals with ARPKD progress to end-stage renal disease (ESRD) within the first decade of life; ESRD may require kidney transplantation.</p>
          <p>Pulmonary hypoplasia resulting from oligohydramnios occurs in a number of affected infants. Approximately 30% of these infants die in the neonatal period or within the first year of life from respiratory insufficiency or superimposed pulmonary infections. With neonatal respiratory support and renal replacement therapies, the long-term survival of these infants has improved to greater than 80%.</p>
          <p>As advances in renal replacement therapy and kidney transplantation improve long-term survival, it is likely that clinical hepatobiliary disease will become a major feature of the natural history of ARPKD. In addition, a subset of individuals with this disorder are identified with hepatosplenomegaly; the renal disease is often mild and may be discovered incidentally during imaging studies of the abdomen.</p>
          <p>Approximately 50% of infants will have clinical evidence of liver involvement at diagnosis although histologic hepatic fibrosis is invariably present at birth. This can lead to progressive portal hypertension with resulting esophageal or gastric varices, enlarged hemorrhoids, splenomegaly, hypersplenism, protein-losing enteropathy, and gastrointestinal bleeding. Other hepatic findings include nonobstructed dilatation of the intrahepatic bile ducts (Caroli syndrome) and dilatation of the common bile duct, which may lead to recurrent or persistent bacterial ascending cholangitis due to dilated bile ducts and stagnant bile flow. An increasing number of affected individuals surviving the neonatal period will eventually require portosystemic shunting or liver transplantation for complications of portal hypertension or cholangitis.</p>
          <p>The classic neonatal presentation of ARPKD notwithstanding, there is significant variability in age and presenting clinical symptoms related to the relative degree of renal and biliary abnormalities.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The suspicion of a diagnosis of ARPKD is based on clinical findings in the proband and the absence of renal disease in the proband's biological parents. Identification of biallelic pathogenic variants in <italic toggle="yes">PKHD1</italic> in the affected individual establishes the diagnosis ARPKD.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Management of affected neonates centers on stabilization of respiratory function by mechanical ventilation and (rarely) unilateral or bilateral nephrectomy if massive kidney enlargement impairs diaphragmatic excursion. Neonates with oliguria or anuria may require peritoneal dialysis within the first days of life, and early recognition and treatment of dehydration and hypertension is critical. Affected children with significant chronic kidney disease should be treated with all modalities of modern pediatric ESRD therapy. Treatment of biliary dysfunction focuses on (1) malabsorption of nutrients and fat-soluble vitamins and (2) the risk for ascending cholangitis, and includes administration of synthetic bile acids and early recognition and treatment of ascending cholangitis. In those with progressive portal hypertension, endoscopy with sclerotherapy or banding of varices may be required. Portosystemic shunting and/or consideration of liver transplantation may be required. Those with ESRD and severe portal hypertension may be candidates for dual renal/liver transplantation.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Ursodiol treatment may increase the amount of bile acid and/or reduce the development of gallstones. Immunization against encapsulated bacteria in those with severe portal hypertension and splenic dysfunction is recommended. Palivizumab (Synagis<sup>&#x000ae;</sup>) for children younger than age 24 months with chronic lung disease and/or prematurity is recommended. Prophylaxis with antibiotics is recommended for those at high risk of developing ascending cholangitis.</p>
          <p><italic toggle="yes">Surveillance:</italic> Regular monitoring of blood pressure, renal function, serum electrolyte concentrations, hydration status, nutritional status, and growth. Hepatobiliary dysfunction leading to portal hypertension is monitored by physical examination evaluating for hepatosplenomagly; regular examination of platelet count, in addition to serum albumin levels, PT/PTT, and 25-OH vitamin D, vitamin E levels, and fat-soluble vitamin levels. Periodic ultrasonography and referral to a hepatologist if hepatomegaly and/or splenomegaly develops; periodic monitoring by esophagogastroduodenoscopy (EGD) to detect esophageal varices. Consideration of MR cholangiography, a more sensitive measurement for biliary ectasia, at baseline and then as indicated.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Sympathomimetic agents in individuals with hypertension; nephrotoxic agents (NSAIDS and aminoglycosides) unless clinically indicated. Potentially hepatotoxic agents (e.g., acetaminophen doses of &#x0003e;30mg/kg/day, herbal supplements, and alcohol) should be minimized. Preclinical data suggest that caffeine, theophylline-like medications, and calcium channel blockers should be avoided unless clinically necessary.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If the pathogenic variants in the family are not known, high-resolution renal and hepatic ultrasonographic evaluation and monitoring of systemic blood pressure may identify disease in sibs of a proband.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>ARPKD is inherited in an autosomal recessive manner. Each sib of a proband has a 25% chance of inheriting both pathogenic variants and being affected, a 50% chance of inheriting a pathogenic variant and being a carrier, and a 25% chance of inheriting neither pathogenic variant and not being a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if both pathogenic variants have been identified in the family. No systematic data are available on the sensitivity and specificity of prenatal ultrasound examination in establishing the diagnosis of ARPKD in pregnancies at 25% risk.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="pkd-ar.Diagnosis">
        <title>Diagnosis</title>
        <sec id="pkd-ar.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Autosomal recessive polycystic kidney disease (ARPKD) <bold>should be suspected</bold> in individuals with bilaterally enlarged, diffusely echogenic kidneys. Diagnosis is typically made based on clinical presentation and radiographic findings [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.hartung.2014.e833">Hartung &#x00026; Guay-Woodford 2014</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner 2014</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.hoyer.2015.186">Hoyer 2015</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>]. Specific diagnostic criteria of ARPKD (modified from <xref ref-type="bibr" rid="pkd-ar.REF.zerres.1996.437">Zerres et al [1996]</xref>):</p>
          <list list-type="bullet">
            <list-item>
              <p><xref ref-type="sec" rid="pkd-ar.Typical_Findings_on_Imaging">Typical findings</xref> on renal imaging</p>
              <p>AND</p>
            </list-item>
            <list-item>
              <p>One or more of the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Imaging findings consistent with biliary ductal ectasia (see <bold>Ultrasonography</bold>)</p>
                </list-item>
                <list-item>
                  <p>Clinical/laboratory signs of congenital hepatic fibrosis (CHF) that leads to portal hypertension and may be indicated by hepatosplenomegaly and/or esophageal varices</p>
                </list-item>
                <list-item>
                  <p>Hepatobiliary pathology demonstrating a characteristic developmental biliary ductal plate abnormality and resultant CHF (see <bold>Childhood and young adulthood</bold>)</p>
                </list-item>
                <list-item>
                  <p>Absence of renal enlargement and/or characteristic imaging findings in both parents, as demonstrated by high-resolution ultrasonography (HRUS) examination</p>
                </list-item>
                <list-item>
                  <p>Pathologic (biopsy or autopsy) or genetic diagnosis of ARPKD in an affected sib</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <sec id="pkd-ar.Typical_Findings_on_Imaging">
            <title>Typical Findings on Imaging</title>
            <p>
              <bold>Ultrasonography</bold>
            </p>
            <p>Ultrasonography (US) is the diagnostic method of choice for assessing fetal and pediatric ARPKD because it is cost effective, painless, widely available, and does not require radiation or sedation. It is predominantly useful in identifying renal abnormalities, but abdominal US may also indicate biliary ductal involvement or splenic enlargement in those with ARPKD. However, renal US alone is never diagnostic (see <related-object link-type="booklink" source-id="gene" document-id="pkd-ad" document-type="chapter">Polycystic Kidney Disease, Autosomal Dominant</related-object>).</p>
            <p>The renal diagnostic criteria for ARPKD detected by ultrasonography are:</p>
            <list list-type="bullet">
              <list-item>
                <p>Increased renal size (in relation to normative size based on age and size of the affected individual);</p>
              </list-item>
              <list-item>
                <p>Increased echogenicity;</p>
              </list-item>
              <list-item>
                <p>Poor corticomedullary differentiation.</p>
              </list-item>
            </list>
            <p>
              <bold>Prenatal</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Sonography may demonstrate echogenic, enlarged, reniform kidneys, oligohydramnios, or an empty urinary bladder in severe cases of ARPKD.</p>
              </list-item>
              <list-item>
                <p>Severely affected fetuses with oligohydramnios may have pulmonary hypoplasia and high mortality due to pulmonary insufficiency, or multiple intrauterine compression anomalies of lethal Potter sequence.</p>
              </list-item>
              <list-item>
                <p>The presence of large reniform echogenic kidneys with poor corticomedullary differentiation and oligohydramnios on prenatal ultrasound examination suggests ARPKD, although other diagnoses are possible.</p>
              </list-item>
            </list>
            <p>
              <bold>Infancy</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>The presence of bilateral palpable flank masses in infants with poorly characterized chronic pulmonary disease, a history of oligohydramnios or spontaneous pneumothorax as a newborn, and hypertension are highly suggestive of ARPKD but not diagnostic.</p>
              </list-item>
              <list-item>
                <p>Biliary findings as noted above, as well as signs of portal hypertension such as hepatosplenomegaly, make a diagnosis of ARPKD more likely.</p>
              </list-item>
            </list>
            <p>
              <bold>Childhood and young adulthood</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>The findings on renal imaging are noted as above and renal size may actually decrease with age as fibrosis progresses.</p>
              </list-item>
              <list-item>
                <p>The hepatobiliary abnormalities with progressive portal hypertension are often the prominent presenting features (see <related-object link-type="booklink" source-id="gene" document-id="hepatic-fibrosis" document-type="chapter">Congenital Hepatic Fibrosis Overview</related-object>).</p>
              </list-item>
            </list>
            <p>Microscopic cystic renal lesions may be present in the early stages with later development of macroscopic cysts.</p>
            <p>Studies suggest that HRUS may significantly improve the diagnosis of mild disease as well as provide noninvasive, detailed definition of kidney manifestations without extensive use of ionizing radiation or contrast agents [<xref ref-type="bibr" rid="pkd-ar.REF.turkbey.2009.100">Turkbey et al 2009</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2010b.972">Gunay-Aygun et al 2010b</xref>].</p>
            <p>Magnetic resonance imaging offers no advantage over HRUS or genetic testing in the diagnosis of ARPKD.</p>
            <p>
              <bold>Magnetic Resonance Cholangiopancreatography</bold>
            </p>
            <p>Imaging findings consistent with biliary ductal ectasia are based on magnetic resonance cholangiopancreatography (MRCP), which provides a clear depiction of the biliary duct system. The findings on MRCP are a sensitive measure of biliary ductal anatomy. Combined with the imaging findings of the kidney, the biliary duct abnormalities are diagnostic of ARPKD and have largely replaced the more invasive analysis of ductal anatomy by liver biopsy [<xref ref-type="bibr" rid="pkd-ar.REF.turkbey.2009.100">Turkbey et al 2009</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2010a.160">Gunay-Aygun et al 2010a</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2013.112">Gunay-Aygun et al 2013</xref>].</p>
            <p>Note: Renal biopsies are not used to diagnose ARPKD.</p>
          </sec>
          <sec id="pkd-ar.Pathology_Biopsy_or_Autopsy">
            <title>Pathology (Biopsy or Autopsy)</title>
            <p>The histologic findings of developmental ductal plate abnormalities, including bile duct proliferation, biliary ectasia, and periportal fibrosis, are present in all individuals with ARPKD [<xref ref-type="bibr" rid="pkd-ar.REF.kamath.2003.857">Kamath &#x00026; Piccoli 2003</xref>].</p>
            <list list-type="bullet">
              <list-item>
                <p>The hepatobiliary disease in ARPKD is the result of a developmental defect where a failure of ductal plate remodeling results in persistence of embryologic bile duct structures; these eventually can become massively dilated.</p>
              </list-item>
              <list-item>
                <p>The dilated bile ducts may evolve into macroscopic cysts that are in connection with the intrahepatic bile ducts and can be detected by imaging modalities, particularly MRCP.</p>
              </list-item>
              <list-item>
                <p>Associated portal veins are often abnormal, demonstrating dilations and an increased number of smaller portal vein branches.</p>
              </list-item>
              <list-item>
                <p>A significant amount of fibrosis may be seen in the portal tract even at birth, and as affected children age, the amount of peri-portal fibrosis increases, resulting in hepatomegaly and progressive portal hypertension.</p>
              </list-item>
            </list>
            <p>Interestingly and for unclear reasons, ARPKD-affected livers often demonstrate proportionally larger left lobes compared to the right lobes [<xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2013.112">Gunay-Aygun et al 2013</xref>].</p>
          </sec>
        </sec>
        <sec id="pkd-ar.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of ARPKD <bold>is established</bold> in a proband with renal cystic enlargement, congenital hepatic fibrosis, and biallelic pathogenic variants in <italic toggle="yes">PKHD1</italic> identified on molecular genetic testing (see <xref ref-type="table" rid="pkd-ar.T.molecular_genetic_testing_used">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">PKHD1</italic> is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">PKHD1</italic> and other genes of interest (see <xref ref-type="sec" rid="pkd-ar.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel that includes <italic toggle="yes">PKHD1</italic>) fails to confirm a diagnosis in an individual with features of ARPKD. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="pkd-ar.T.molecular_genetic_testing_used" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in ARPKD</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pkd-ar.T.molecular_genetic_testing_used_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_pkd-ar.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_pkd-ar.T.molecular_genetic_testing_used_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pkd-ar.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">PKHD1</italic>
                  </td>
                  <td headers="hd_h_pkd-ar.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_pkd-ar.T.molecular_genetic_testing_used_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~73%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_pkd-ar.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_pkd-ar.T.molecular_genetic_testing_used_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1-2%&#x000a0;<sup>4,&#x000a0;6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="pkd-ar.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="pkd-ar" object-id="pkd-ar.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="pkd-ar.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="pkd-ar.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="pkd-ar.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="pkd-ar.TF.1.4">
                <label>4. </label>
                <p>
                  <xref ref-type="bibr" rid="pkd-ar.REF.melchionda.2016.811">Melchionda et al [2016]</xref>
                </p>
              </fn>
              <fn id="pkd-ar.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="pkd-ar.TF.1.6">
                <label>6. </label>
                <p>In three of 16 persons with ARPKD in whom only one pathogenic variant was detected by sequence analysis, three different <italic toggle="yes">PKHD1</italic> deletions were identified using MLPA [<xref ref-type="bibr" rid="pkd-ar.REF.zvereff.2010.505">Zvereff et al 2010</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="pkd-ar.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="pkd-ar.Clinical_Description">
          <title>Clinical Description</title>
          <p>Autosomal recessive polycystic kidney disease (ARPKD) belongs to a group of congenital hepatorenal fibrocystic syndromes and is a cause of significant renal and liver-related morbidity and mortality in children. The two organ systems primarily affected are kidney and liver; secondary effects are seen in several other organ systems.</p>
          <p><bold>Presentation.</bold> The majority of affected individuals present in the neonatal period. With modern obstetric ultrasonography, the diagnosis may be suspected when abnormalities are detected by prenatal ultrasound examination. Severely affected fetuses detected during prenatal ultrasound display a &#x0201c;Potter-like&#x0201d; oligohydramnios phenotype with lethal pulmonary hypoplasia and massively enlarged echogenic kidneys, which can compromise normal delivery.</p>
          <p>Due to its wide clinical variability, the diagnosis of ARPKD may be made during any stage of childhood; in rare cases it does not present until adolescence or adulthood [<xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2010b.972">Gunay-Aygun et al 2010b</xref>]. A minority of affected individuals present as older children or young adults with evidence of hepatic dysfunction as the prominent presenting feature (see <bold>Liver</bold>).</p>
          <p><bold>Kidney.</bold> Large bilateral flank masses (nephromegaly) are invariably present on physical examination.</p>
          <list list-type="bullet">
            <list-item>
              <p>Urine output is usually not diminished; polyuria and polydipsia are consistent with a renal concentrating defect. However, oliguria and overt acute renal failure may be seen in the first week of life.</p>
            </list-item>
            <list-item>
              <p>Hyponatremia is often present in the neonatal period but usually resolves unless renal failure is present.</p>
            </list-item>
            <list-item>
              <p>Renal function (as reflected in serum concentrations of creatinine and blood urea nitrogen [BUN]) is often impaired. Apparent improvement in renal function over time occurs with progression of normal kidney development over the first three years of life.</p>
            </list-item>
            <list-item>
              <p>Hypertension, often severe, is usually noted within the first few weeks of life but may improve over time with developmental maturation.</p>
            </list-item>
          </list>
          <p><bold>End-stage renal disease (ESRD).</bold> More than 50% of affected individuals progress to ESRD, usually in the first decade of life [<xref ref-type="bibr" rid="pkd-ar.REF.hoyer.2015.186">Hoyer 2015</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>]. ESRD may require kidney transplantation (see <xref ref-type="sec" rid="pkd-ar.Management">Management</xref>).</p>
          <list list-type="bullet">
            <list-item>
              <p>Perinatal presentation and corticomedullary involvement demonstrated by high-resolution ultrasound examination are associated with more rapid progression of renal disease [<xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2010b.972">Gunay-Aygun et al 2010b</xref>].</p>
            </list-item>
            <list-item>
              <p>In a large cohort of neonatal survivors, actuarial kidney survival rates were 86% at age five years, 71% at age ten years, and 42% at age 20 years [<xref ref-type="bibr" rid="pkd-ar.REF.bergmann.2005.829">Bergmann et al 2005</xref>].</p>
            </list-item>
          </list>
          <p><bold>Liver.</bold> As advances in renal replacement therapy and kidney transplantation improve long-term survival, it is likely that clinical hepatobiliary disease will become a major feature of the natural history of ARPKD [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner 2014</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>].</p>
          <p><bold>Congenital hepatic fibrosis (CHF).</bold> The invariant liver lesion of ARPKD (also known as CHF) is a developmental abnormality of biliary ductal plate remodeling.</p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with CHF develop progressive portal hypertension with resulting esophageal or gastric varices, enlarged hemorrhoids, splenomegaly, hypersplenism, protein-losing enteropathy, and gastrointestinal bleeding [<xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>].</p>
              <list list-type="bullet">
                <list-item>
                  <p>Up to 70% of affected individuals (including long-term survivors with classic presentations and those who present with predominantly hepatobiliary disease) develop portal hypertension due to progressive periportal fibrosis; bleeding from esophageal varices contributes significantly to the morbidity and mortality of the disease [<xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2013.112">Gunay-Aygun et al 2013</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner 2014</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Although histologic hepatic fibrosis is invariably present at birth, clinical, radiographic, or laboratory evidence of liver disease may be absent in newborns [<xref ref-type="bibr" rid="pkd-ar.REF.shneider.2005.634">Shneider &#x00026; Magid 2005</xref>]. In 115 children with ARPKD with a mean age at diagnosis of 29 days, <xref ref-type="bibr" rid="pkd-ar.REF.zerres.1996.437">Zerres et al [1996]</xref> found that 45% had clinical evidence of liver involvement at presentation.</p>
            </list-item>
          </list>
          <p><bold>Caroli syndrome.</bold> In addition to CHF, nonobstructed dilatation of the intrahepatic bile ducts (Caroli syndrome) and dilatation of the common bile duct occur in more than 60% of individuals with ARPKD.</p>
          <list list-type="bullet">
            <list-item>
              <p>The resultant abnormal hepatobiliary drainage contributes to a significant risk for recurrent or persistent bacterial ascending cholangitis with sepsis.</p>
            </list-item>
            <list-item>
              <p>Cholestasis may also lead to malabsorption of fat-soluble vitamins (A, D, E, and K).</p>
            </list-item>
            <list-item>
              <p>The overall abnormal proliferation of biliary cells has reportedly led to benign or malignant tumors in older individuals. Cholangiocarcinoma has been reported in individuals with ARPKD in adulthood [<xref ref-type="bibr" rid="pkd-ar.REF.fonck.2001.1648">Fonck et al 2001</xref>].</p>
            </list-item>
          </list>
          <p><bold>Hepatosplenomegaly.</bold> A subset of individuals with ARPKD are identified with hepatosplenomegaly [<xref ref-type="bibr" rid="pkd-ar.REF.roy.1997.302">Roy et al 1997</xref>]; the renal disease is often mild and may be discovered incidentally during imaging studies of the abdomen.</p>
          <list list-type="bullet">
            <list-item>
              <p>In a well-studied National Institutes of Health (NIH) cohort of 73 individuals who had confirmed ARPKD, splenomegaly was found to be an early indicator of biliary dysfunction [<xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2013.112">Gunay-Aygun et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>Splenomegaly was found in 60% of the affected children younger than age five years but did not correlate with renal function, the type of <italic toggle="yes">PKHD1</italic> variant, or severity of renal disease [<xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2013.112">Gunay-Aygun et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>In a study that challenged many assumptions about the timing of liver involvement in ARPKD, <xref ref-type="bibr" rid="pkd-ar.REF.adeva.2006.1">Adeva et al [2006]</xref> reported that nearly one third of individuals with pathogenic variants in <italic toggle="yes">PKHD1</italic> and hepatic involvement were older than age 20 years at the time of initial presentation.</p>
            </list-item>
            <list-item>
              <p>This wide variability in age of diagnosis was confirmed in a cohort of 78 affected individuals enrolled in an NIH natural history study, in which affected individuals ranged in age from one to 56 years [<xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2010a.160">Gunay-Aygun et al 2010a</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2010b.972">Gunay-Aygun et al 2010b</xref>], demonstrating that the clinical spectrum of ARPKD/CHF is much broader than previously assumed.</p>
            </list-item>
          </list>
          <p><bold>Lung.</bold> Pulmonary hypoplasia resulting from oligohydramnios occurs to varying degrees in a number of affected infants and is a major cause of morbidity and mortality in the newborn period. Massively enlarged kidneys may also lead to hypoventilation and respiratory distress as a result of limitation of diaphragmatic excursion.</p>
          <list list-type="bullet">
            <list-item>
              <p>In contrast to neonates with other disorders complicated by oligohydramnios, a small proportion of newborns with ARPKD and oligo- or anhydramnios in the third trimester may have relatively minor lung disease [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>]. The reason for this is unclear, but the authors speculate that intrauterine renal overproduction of growth factors critical for lung development (including members of the epidermal growth factor axis) may have an as-yet unexplained positive effect on lung development.</p>
            </list-item>
            <list-item>
              <p>Long-term pulmonary function appears to be good unless patients with ARPKD require mechanical ventilation in the newborn period [<xref ref-type="bibr" rid="pkd-ar.REF.jahnukainen.2015.944">Jahnukainen et al 2015</xref>].</p>
            </list-item>
          </list>
          <p><bold>Dysmorphic features.</bold> Facial characteristics associated with the oligohydramnios sequence including low-set ears, micrognathia, flattened nose, limb positioning defects, and growth deficiency may be present.</p>
          <p>
            <bold>Other</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Recent data suggest that with aggressive nutritional support, growth may be normal in a significant number of children [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>]. Aggressive nutritional support in the first two years of life has dramatically improved growth rates even in children with significant renal impairment and portal hypertension [<xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>Feeding difficulties may result from mechanical compression of the stomach by enlarged kidneys, liver, or spleen, the latter a complication of portal hypertension. Alternatively, significant renal impairment may result in feeding difficulties, loss of appetite, and/or impaired gastric motility.</p>
            </list-item>
            <list-item>
              <p>Cerebral aneurysm, a potentially severe complication of <related-object link-type="booklink" source-id="gene" document-id="pkd-ad" document-type="chapter">autosomal dominant polycystic kidney disease</related-object> (ADPKD), has been reported in two adults and a child with ARPKD [<xref ref-type="bibr" rid="pkd-ar.REF.chalhoub.2013.114">Chalhoub et al 2013</xref>]. Despite the increased incidence of aneurysms in ADPKD and the interactions between ADPKD and ARPKD proteins there is no evidence to date that aneurysms are an extrarenal manifestation of ARPKD [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney &#x00026; Gunay-Aygun et al 2016</xref>].</p>
            </list-item>
            <list-item>
              <p>Children with ARPKD appear to have neurocognitive functioning comparable to other children with a similar degree of chronic kidney disease. Neurocognitive functioning includes intellectual functioning, academic achievement, attention regulation, executive functioning, and behavior [<xref ref-type="bibr" rid="pkd-ar.REF.hartung.2014.1957">Hartung et al 2014</xref>].</p>
            </list-item>
          </list>
          <p><bold>Mortality.</bold> Although the short- and long-term mortality rates of ARPKD are significant, the survival of children with ARPKD has improved significantly with modern neonatal respiratory support and renal replacement therapies.</p>
          <list list-type="bullet">
            <list-item>
              <p>Approximately 23%-30% of affected infants die in the neonatal period or within the first year of life, primarily of respiratory insufficiency or superimposed pulmonary infections [<xref ref-type="bibr" rid="pkd-ar.REF.hoyer.2015.186">Hoyer 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>Of those who survive beyond the first year of life (with the use of dialysis and kidney and/or liver transplantation as indicated), one-year survival is approximately 85%-87% [<xref ref-type="bibr" rid="pkd-ar.REF.guaywoodford.2003.1072">Guay-Woodford &#x00026; Desmond 2003</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.bergmann.2005.829">Bergmann et al 2005</xref>] and ten-year survival is 82% [<xref ref-type="bibr" rid="pkd-ar.REF.hoyer.2015.186">Hoyer 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>Despite improved survival, morbidity of this dual organ disease is significant due to the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Renal collecting duct ectatic cysts and marked renal enlargement, leading to systemic hypertension and progressive renal failure</p>
                </list-item>
                <list-item>
                  <p>Biliary dysgenesis, leading to abnormal bile duct formation with progressive periportal congenital hepatic fibrosis</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Kidney and liver transplantation.</bold> For individuals with ARPKD who undergo kidney transplantation, allograft survival rates are comparable to those in individuals without ARPKD [<xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>]. It is estimated that approximately 10% of affected children surviving the neonatal period will require liver transplantation [<xref ref-type="bibr" rid="pkd-ar.REF.wen.2011.460">Wen 2011</xref>].</p>
          <p>Of those affected individuals who succumb after kidney transplant, 64%-80% of the time mortality is directly attributable to cholangitis/sepsis, a consequence of hepatobiliary disease [<xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>A significant number of individuals with ARPKD who require a renal transplant also suffer from significant hepatobiliary disease and progressive portal hypertension that will most likely require portosystemic shunting or a liver transplant in the future [<xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2013.112">Gunay-Aygun et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>Risk/benefit analysis suggests that individuals who have severe renal and severe hepatobiliary disease will have less morbidity and mortality if they undergo a liver transplant at the same time as their renal transplant (a dual organ transplant) [<xref ref-type="bibr" rid="pkd-ar.REF.chandar.2015.1233">Chandar et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>An algorithm for management and evaluation of the risk/benefit of dual organ transplant in individuals with ARPKD who have both severe kidney and liver disease has been proposed to assist clinicians in the decision-making process [<xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>] (see <xref ref-type="sec" rid="pkd-ar.Management">Management</xref>).</p>
            </list-item>
          </list>
        </sec>
        <sec id="pkd-ar.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No genotype-phenotype correlations have been established to date. Most <italic toggle="yes">PKHD1</italic> pathogenic variants are &#x0201c;private&#x0201d; or unique to single families [<xref ref-type="bibr" rid="pkd-ar.REF.bergmann.2004.453">Bergmann et al 2004</xref>].</p>
          <p>In a study of 73 persons with ARPKD of varying ages, variant type did not correlate with kidney size or function [<xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2010a.160">Gunay-Aygun et al 2010a</xref>]. <xref ref-type="bibr" rid="pkd-ar.REF.frank.2014.1729">Frank et al [2014]</xref> identified four affected persons who survived the neonatal period despite each carrying a homozygous <italic toggle="yes">PKHD1</italic> pathogenic variant expected to lead to premature termination of translation (usually incompatible with life).</p>
          <p>Modifying genes, epigenetic changes, and variations in other non-coding regions of the genome are believed to be responsible for the wide interfamilial clinical variability [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner 2014</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>].</p>
        </sec>
        <sec id="pkd-ar.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance is 100%; significant intrafamilial variation in disease severity is observed [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner 2014</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>].</p>
        </sec>
        <sec id="pkd-ar.Nomenclature">
          <title>Nomenclature</title>
          <p>ARPKD has also been referred to as &#x0201c;infantile polycystic kidney disease&#x0201d;. In their original description of polycystic kidney disease in childhood, <xref ref-type="bibr" rid="pkd-ar.REF.blyth.1971.257">Blyth &#x00026; Ockenden [1971]</xref> used clinical and histologic findings in the kidneys and liver to categorize childhood PKD as perinatal, neonatal, infantile, and juvenile, suggesting four distinct diseases or &#x0201c;stages of disease.&#x0201d; Subsequently, families with multiple affected sibs (see, e.g., <xref ref-type="bibr" rid="pkd-ar.REF.kaplan.1988.639">Kaplan et al [1988]</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.guaywoodford.2003.1072">Guay-Woodford &#x00026; Desmond [2003]</xref>) provided evidence that these distinctions were not meaningful.</p>
          <p>The most recent trend is to refer to this condition as ARPKD/CHF; at least one patient advocacy group, the ARPKD/CHF Alliance, has adopted this terminology (see <xref ref-type="sec" rid="pkd-ar.Resources">Resources</xref>).</p>
        </sec>
        <sec id="pkd-ar.Prevalence">
          <title>Prevalence</title>
          <p>The incidence of ARPKD is estimated at 1:10,000 to 1:40,000. The true incidence may be underestimated because of the failure to correctly diagnose persons of all ages, ranging from newborns to young adults [<xref ref-type="bibr" rid="pkd-ar.REF.adeva.2006.1">Adeva et al 2006</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2010a.160">Gunay-Aygun et al 2010a</xref>].</p>
          <p>The carrier frequency for a <italic toggle="yes">PKHD1</italic> pathogenic variant in the general population has been estimated at 1:70 [<xref ref-type="bibr" rid="pkd-ar.REF.zerres.1998.303">Zerres et al 1998</xref>].</p>
        </sec>
      </sec>
      <sec id="pkd-ar.Genetically_Related_Allelic_Disor">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">PKHD1</italic>.</p>
      </sec>
      <sec id="pkd-ar.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Renal manifestations.</bold> Disorders with cystic renal disease include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="pkd-ad" document-type="chapter"><bold>Autosomal dominant polycystic kidney disease</bold></related-object>
<bold>(ADPKD)</bold> is characterized by progressive cyst development and bilaterally enlarged polycystic kidneys. ADPKD is a systemic disease with cysts in other organs (e.g., the liver, seminal vesicles, pancreas, and arachnoid membrane) and non-cystic abnormalities (e.g., intracranial aneurysms and dolichoectasias, dilatation of the aortic root and dissection of the thoracic aorta, mitral valve prolapse, colonic diverticulae, abdominal wall hernias). In approximately 85% of individuals with ADPKD, a pathogenic variant in <italic toggle="yes">PKD1</italic> is causative; in approximately 15%, a pathogenic variant in <italic toggle="yes">PKD2</italic> is causative.</p>
            <p>Although most ADPKD presents in adulthood, 1%-2% of affected individuals present as newborns, often with signs and symptoms indistinguishable from those of ARPKD [<xref ref-type="bibr" rid="pkd-ar.REF.guaywoodford.1998.173">Guay-Woodford et al 1998</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner 2014</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>]. Renal ultrasonography may distinguish between the two: bilateral macrocysts are typical of ADPKD. Early in the course of ADPKD, especially in younger children, renal involvement may be unilateral. As ADPKD progresses involvement becomes bilateral; cysts can become massive.</p>
            <p>Congenital hepatic fibrosis (CHF), an invariable finding in ARPKD, is rarely observed in ADPKD [<xref ref-type="bibr" rid="pkd-ar.REF.obrien.2012.83">O'Brien et al 2012</xref>].</p>
            <p>Because ADPKD may not present until the third or fourth decade of life, an asymptomatic parent may not be identified as having ADPKD until after the birth of an affected child [<xref ref-type="bibr" rid="pkd-ar.REF.fick.1993.1863">Fick et al 1993</xref>]. Renal ultrasound examination of the parents of any individual with atypical ARPKD or suspected ADPKD is needed to evaluate for possible previously undiagnosed ADPKD. Of note: (1)</p>
            <list list-type="bullet">
              <list-item>
                <p><xref ref-type="bibr" rid="pkd-ar.REF.pei.2009.205">Pei et al [2009]</xref> observed that it may not be possible to exclude the diagnosis of ADPKD in a small subset of persons (i.e., those with PKD2 pathogenic variants) until age 40 years;</p>
              </list-item>
              <list-item>
                <p>Approximately 5%-10% of individuals with ADPKD have a <italic toggle="yes">de novo</italic> pathogenic variant, and thus do not have an affected parent.</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>Glomerulocystic kidney disease (GCKD),</bold> a disorder that typically presents in the neonatal period with large palpable flank masses, may be clinically indistinguishable from ARPKD. Findings on renal ultrasound examination may also resemble those seen in ARPKD: diffusely enlarged echogenic kidneys and occasional macrocysts. Histologic examination shows dilatation of Bowman's capsule and dysplasia with abnormal medullary differentiation. Ten percent have involvement of the intrahepatic bile ducts, similar to the biliary ductal plate abnormality of ARPKD.</p>
            <p>GCKD can be a subtype of ADPKD; however, in at least one large kindred, linkage to both ADPKD loci was excluded [<xref ref-type="bibr" rid="pkd-ar.REF.sharp.1997.77">Sharp et al 1997</xref>]. GCKD also occurs as part of genetic disorders including the <related-object link-type="booklink" source-id="gene" document-id="tuberous-sclerosis" document-type="chapter">tuberous sclerosis complex</related-object>, <related-object link-type="booklink" source-id="gene" document-id="ofd1" document-type="chapter">orofacial digital syndrome type 1</related-object>, trisomy 13, brachymesomelia-renal syndrome, and short rib-polydactyly syndrome.</p>
          </list-item>
          <list-item>
            <p><bold>Renal cysts and diabetes syndrome (RCAD)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/137920">137920</ext-link>). Pathogenic variants in a gene that encodes for the transcription factor hepatocyte nuclear factor 1 beta (<italic toggle="yes">HNF1&#x003b2;</italic>) represent the most common known monogenetic cause of developmental kidney disease [<xref ref-type="bibr" rid="pkd-ar.REF.clissold.2015.102">Clissold et al 2015</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.verhave.2016.345">Verhave et al 2016</xref>]. This disorder is the leading cause of hyperechoic enlarged or normal-sized fetal kidneys, which often lead to a misdiagnosis of ARPKD. Renal cysts are the most frequently detected feature of <italic toggle="yes">HNF1&#x003b2;</italic>-associated kidney disease, although other renal phenotypes (single kidney, renal hypoplasia/dysplasia) can also occur. Extrarenal phenotypes are common and <italic toggle="yes">HNF1&#x003b2;</italic> was first identified as a disease gene for diabetes (MODY5). Other phenotypes reported (which serve to differentiate this genetic disorder from ARPKD) include genital malformations, autism, epilepsy, gout, hypomagnesemia, hyperthyroidism, liver and intestinal abnormalities, and a rare form of kidney cancer [<xref ref-type="bibr" rid="pkd-ar.REF.bockenhauer.2016.707">Bockenhauer &#x00026; Jaureguiberry 2016</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.limwongse.2016">Limwongse 2016</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Diffuse cystic dysplasia</bold> is characterized by ultrasonographic findings of large echogenic kidneys and histologic findings of disorganized, poorly differentiated nephron segments with primitive elements such as cartilage [<xref ref-type="bibr" rid="pkd-ar.REF.watkins.1999">Watkins et al 1999</xref>]. Diffuse cystic dysplasia can occur sporadically or more commonly as a component of numerous syndromes (e.g., <related-object link-type="booklink" source-id="gene" document-id="joubert" document-type="chapter">Joubert syndrome</related-object>, Meckel-Gruber syndrome, Jeune asphyxiating thoracic dystrophy) [<xref ref-type="bibr" rid="pkd-ar.REF.limwongse.1999">Limwongse et al 1999</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.limwongse.2016">Limwongse 2016</xref>]. In these syndromes, the extrarenal or extrahepatic abnormalities clinically predominate; the diffuse cystic dysplasia remains a more minor feature.</p>
          </list-item>
          <list-item>
            <p><bold>Other "polycystic kidney" diseases.</bold> A number of studies report "polycystic kidneys" as a component of numerous congenital syndromes. In fact, many of these reports may be describing syndromic forms of cystic dysplasia.</p>
            <p>There are a number of diseases where renal cysts are a pathologic finding. These differ from ARPKD in that the renal cysts represent only one component of multiple developmental abnormalities that characterize the syndrome [<xref ref-type="bibr" rid="pkd-ar.REF.limwongse.2016">Limwongse 2016</xref>]. A syndrome of neonatal diabetes mellitus, congenital hypothyroidism, hepatic fibrosis, PKD, and congenital glaucoma has been described in two sibs. Liver biopsy confirmed the classic findings of CHF; histologic evaluation of the kidneys was not performed (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/601331">601331</ext-link>).</p>
          </list-item>
        </list>
        <p><bold>Disorders</bold> with renal involvement that may mimic ARPKD in the neonatal period include malignancies such as leukemia or Wilms tumor (see <related-object link-type="booklink" source-id="gene" document-id="wilms-ov" document-type="chapter">Wilms Tumor Overview</related-object>), bilateral renal vein thrombosis, and radiocontrast nephropathy [<xref ref-type="bibr" rid="pkd-ar.REF.guaywoodford.1998.173">Guay-Woodford et al 1998</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>].</p>
        <p><bold>Liver manifestations.</bold> Other hepatorenal disorders characterized by renal cystic changes and hepatic fibrosis to consider include a number of disorders already mentioned: juvenile nephronophthisis and multisystem disorders such as Meckel-Gruber syndrome, <related-object link-type="booklink" source-id="gene" document-id="bbs" document-type="chapter">Bardet-Biedl syndrome</related-object>, <related-object link-type="booklink" source-id="gene" document-id="joubert" document-type="chapter">Joubert syndrome</related-object>, and Jeune asphyxiating thoracic dystrophy [<xref ref-type="bibr" rid="pkd-ar.REF.johnson.2003.311">Johnson et al 2003</xref>]. In these autosomal recessive disorders the kidneys are usually small or normal in size, in contrast to the enlarged kidneys of ARPKD (see <related-object link-type="booklink" source-id="gene" document-id="hepatic-fibrosis" document-type="chapter">Congenital Hepatic Fibrosis Overview</related-object>).</p>
      </sec>
      <sec id="pkd-ar.Management">
        <title>Management</title>
        <sec id="pkd-ar.Evaluations_Following_Initial_Dia">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with autosomal recessive polycystic kidney disease (ARPKD), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Respiratory status, including physical examination, pulse oximetry, and chest radiographs (as indicated)</p>
            </list-item>
            <list-item>
              <p>Tests of renal function, including serum concentrations of BUN, creatinine, and cystatin C, which allows a more accurate estimation of glomerular filtration rate (GFR) [<xref ref-type="bibr" rid="pkd-ar.REF.gunayaygun.2010a.160">Gunay-Aygun et al 2010a</xref>]</p>
            </list-item>
            <list-item>
              <p>Serum electrolyte concentrations to identify electrolyte abnormalities (e.g., hyponatremia, hyperkalemia)</p>
            </list-item>
            <list-item>
              <p>Urinalysis to assess for the urinary concentration and proteinuria. Clinical assessment of intravascular volume status for possible volume depletion or overload.</p>
              <p>Note: White blood cells are commonly present in the urine of children with ARPKD and may not represent infection. If there is a clinical suspicion of urinary tract infection, a urine culture should be obtained before initiating treatment.</p>
            </list-item>
            <list-item>
              <p>Renal ultrasonography (consider high-resolution technology when available)</p>
            </list-item>
            <list-item>
              <p>Measurement of blood pressure. If elevated, home blood pressure monitoring can be helpful in distinguishing fixed hypertension from &#x0201c;white coat&#x0201d; hypertension (i.e., high blood pressure that occurs during medical examinations).</p>
            </list-item>
            <list-item>
              <p>Assessment of feeding, weight gain, and linear growth with formal nutrition consultation as appropriate</p>
            </list-item>
            <list-item>
              <p>Measurement of liver transaminases, serum bile acids, hepatic synthetic function (e.g., by assessing serum albumin concentration, 25-OH vitamin D levels, vitamin E levels and coagulation studies), fat-soluble vitamin levels, complete blood counts, physical examination for hepatomegaly/splenomegaly, and abdominal ultrasonography to assess the clinical extent of liver involvement</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="pkd-ar.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>(See recent comprehensive reviews including <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner [2011]</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al [2013]</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.guaywoodford.2014.611">Guay-Woodford et al [2014]</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner [2014]</xref>, and <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al [2016]</xref> for detailed management strategies.)</p>
          <p>Initial management of affected infants centers on stabilization of respiratory function.</p>
          <p>
            <bold>Respiratory</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Mechanical ventilation may be necessary to treat pulmonary hypoplasia (characterized by inability to oxygenate despite jet or oscillating ventilation with 100% oxygen) or hypoventilation from massively enlarged kidneys (characterized by increased pCO<sub>2</sub> despite adequate oxygenation). It may also be required in the first 48-72 hours postnatally to determine whether pulmonary hypoplasia or reversible pulmonary disease is present.</p>
            </list-item>
            <list-item>
              <p>When massively enlarged kidneys prevent diaphragmatic excursion and/or cause severe feeding intolerance, some have advocated unilateral or bilateral nephrectomy [<xref ref-type="bibr" rid="pkd-ar.REF.shukla.2004.2000">Shukla et al 2004</xref>].</p>
              <list list-type="bullet">
                <list-item>
                  <p>Experience suggests that unilateral nephrectomy may be of limited value, since the contralateral kidney often shows marked enlargement following unilateral nephrectomy [Author, unpublished observations]</p>
                </list-item>
                <list-item>
                  <p>Bilateral nephrectomy with placement of a peritoneal dialysis catheter followed by a short period of hemodialysis often allows the peritoneum to heal in preparation for chronic peritoneal dialysis [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>]. The timing of these procedures, as well as potential coordination with a preemptive living donor transplantation, will be dictated by factors such as the age, size, and clinical status of the patient as well as living donor availability.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Renal</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Neonates with oliguria or anuria may require peritoneal dialysis within the first days of life.</p>
            </list-item>
            <list-item>
              <p>Hyponatremia is common and should be treated depending on the individual's volume status.</p>
            </list-item>
            <list-item>
              <p>Early recognition and treatment of dehydration is critical. Supplemental feedings or fluid therapy via nasogastric or gastrostomy tubes may be required.</p>
            </list-item>
            <list-item>
              <p>Hypertension generally responds well to angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor inhibitors (ARBs), which are the treatments of choice. In many cases, hypertension may be severe enough to require multiple antihypertensive medications.</p>
            </list-item>
            <list-item>
              <p>Affected children with significant chronic kidney disease should be treated with all modalities of modern pediatric end-stage renal disease (ESRD) therapy, including dialysis and kidney transplantation.</p>
            </list-item>
            <list-item>
              <p>Anemia in children with Stage III or higher chronic kidney disease may require treatment with iron supplementation and erythropoietin-stimulating agents (ESAs).</p>
            </list-item>
          </list>
          <p><bold>Liver.</bold> Treatment of biliary dysfunction focuses on: (1) malabsorption of nutrients and fat-soluble vitamins; and (2) the risk for ascending cholangitis.</p>
          <list list-type="bullet">
            <list-item>
              <p>Administration of synthetic bile acids</p>
              <list list-type="bullet">
                <list-item>
                  <p>The presence of poor serum levels of fat-soluble vitamins (K, D, E, A) or poor weight gain despite adequate caloric supplementation may indicate the need for bile acid supplementation.</p>
                </list-item>
                <list-item>
                  <p>Clinical suspicion of bile acid deficiency may be verified by measurement of serum bile acids.</p>
                </list-item>
                <list-item>
                  <p>Administration of synthetic bile acids is indicated if there is evidence of significant intrahepatic ductal dilation (Caroli syndrome), which can be appreciated by magnetic resonance cholangiopancreatography (MRCP).</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Bacterial cholangitis, often an underdiagnosed complication in those with hepatic involvement, may present as recurrent bacteremia with enteric pathogens without typical clinical features of cholangitis. Persistent fevers, particularly with right upper-quadrant pain, should be evaluated and treated aggressively.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Alkaline phosphatase and &#x003b3;GTP may be elevated during episodes of acute ascending cholangitis and may be helpful in establishing a diagnosis [<xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Esophageal varices should be treated with endoscopic banding or sclerotherapy as indicated.</p>
            </list-item>
            <list-item>
              <p>Portosystemic shunting may be necessary to treat progressive portal hypertension; however, <xref ref-type="bibr" rid="pkd-ar.REF.tsimaratos.2000.856">Tsimaratos et al [2000]</xref> reported recurrent hepatic encephalopathy and death following portocaval shunting in two individuals with ARPKD who had ESRD.</p>
            </list-item>
            <list-item>
              <p>In severe instances of intractable portal hypertension, or severe dual renal and hepatobiliary disease, hepatic or dual renal-hepatic transplantation has become a viable option [<xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.chandar.2015.1233">Chandar et al 2015</xref>].</p>
            </list-item>
          </list>
          <p><bold>Dual-organ transplantation.</bold> Successful simultaneous liver-kidney transplantation in individuals with ARPKD has been reported in a small case series [<xref ref-type="bibr" rid="pkd-ar.REF.harps.2011.1127">Harps et al 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.chapal.2012.2083">Chapal et al 2012</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.brinkert.2013.640">Brinkert et al 2013</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>Previously, only a small percent of individuals with ARPKD, particularly those diagnosed later in life, have required liver transplantation. However, with improved survival and advances in renal replacement therapy, it is likely that the number of individuals with ARPKD requiring liver transplantation may increase.</p>
            </list-item>
          </list>
          <p>An algorithm for evaluating the risk benefit of dual organ transplant in individuals with ARPKD who have both severe kidney and liver disease has been proposed to assist clinicians in the decision-making process [<xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>]. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="pkd-ar-Table2.pdf" content-type="local-data">Table 2</inline-supplementary-material> (pdf) and <xref ref-type="fig" rid="pkd-ar.F1">Figure 1</xref>.</p>
          <p>
            <bold>Feeding and growth</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Feeding intolerance and growth failure, even in the absence of renal insufficiency, can be significant, especially in young infants. Aggressive nutritional support, which may include supplemental feedings via nasogastric or gastrostomy tubes, is often required to optimize weight gain and growth [<xref ref-type="bibr" rid="pkd-ar.REF.dell.2009">Dell et al 2009</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.hartung.2014.e833">Hartung &#x00026; Guay-Woodford 2014</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner 2014</xref>].</p>
            </list-item>
            <list-item>
              <p>Children with growth failure may benefit from treatment with growth hormone [<xref ref-type="bibr" rid="pkd-ar.REF.lilova.2003.57">Lilova et al 2003</xref>]. The optimal age for starting growth hormone therapy depends on the growth velocity of the child; studies suggest that treatment is beneficial in children with chronic kidney disease who are age two years or younger [<xref ref-type="bibr" rid="pkd-ar.REF.seikaly.2007.1195">Seikaly et al 2007</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.schaeffer.2016">Schaeffer 2016</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="pkd-ar.Prevention_of_Secondary_Complicat">
          <title>Prevention of Secondary Complications</title>
          <p>Ursodeoxycholic acid (ursodiol or Actigall<sup>&#x000ae;</sup>) is a bile acid that can be used to increase the amount and flow of bile and/or to reduce the development of gallstones in individuals with ARPKD who have significant hepatobiliary disease.</p>
          <p>With severe portal hypertension and splenic dysfunction, immunization against encapsulated bacteria (pneumococcus; <italic toggle="yes">H. influenza</italic> type B; meningococcus) is indicated.</p>
          <p>Updated guidelines advise that palivizumab (Synagis<sup>&#x000ae;</sup>) be administered to at-risk children younger than age 24 months who have chronic lung disease and/or a history of prematurity [<xref ref-type="bibr" rid="pkd-ar.REF.committee_on_infectious_diseases.2009.1694">Committee on Infectious Diseases 2009</xref>].</p>
          <p>Although the role of chronic antibiotic prophylaxis in all children with ARPKD remains controversial, prophylaxis with antibiotics is recommended for persons with ARPKD who are at high risk of developing ascending cholangitis, including those who have experienced an episode of ascending cholangitis in the past.</p>
        </sec>
        <sec id="pkd-ar.Surveillance">
          <title>Surveillance</title>
          <p>The following should be monitored regularly, depending on disease course and complications:</p>
          <list list-type="bullet">
            <list-item>
              <p>Blood pressure monitored at periodic physician's visits as well as home blood pressure monitoring if indicated (see <xref ref-type="sec" rid="pkd-ar.Evaluations_Following_Initial_Dia">Evaluations Following Initial Diagnosis</xref>)</p>
            </list-item>
            <list-item>
              <p>Renal function in those with chronic kidney disease Stage III or less; close monitoring for the complications of CKD should be undertaken by the treating nephrologist according to standard practices outlined in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ajkd.org/content/kdoqiguidelines">KDOQI Guidelines</ext-link>.</p>
            </list-item>
            <list-item>
              <p>Electrolyte balance, monitored by obtaining serum concentrations of sodium, potassium, and chloride. Mineral balance, monitored by assessing calcium and phosphorous. If the calcium level is low, magnesium concentration should be evaluated [<xref ref-type="bibr" rid="pkd-ar.REF.dell.2009">Dell et al 2009</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner 2014</xref>].</p>
            </list-item>
            <list-item>
              <p>Hydration status</p>
            </list-item>
            <list-item>
              <p>Nutritional status, with growth plotted on standard growth charts and nutrition consultation as indicated</p>
            </list-item>
            <list-item>
              <p>Hepatoportal duct involvement, by physical examination and complete blood counts, in addition to serum albumin levels, PT/PTT, and 25-OH vitamin D, vitamin E levels, and fat-soluble vitamin levels</p>
            </list-item>
            <list-item>
              <p>If hepatomegaly is present and/or splenomegaly develops, additional monitoring including periodic ultrasonography or MRI. With hepatosplenomegaly, referral to a pediatric hepatologist is suggested for evaluation and periodic monitoring by esophagogastroduodenoscopy (EGD) to detect esophageal varices [<xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>Consideration of MR cholangiography, a more sensitive measurement for biliary ectasia, at baseline and then as indicated [<xref ref-type="bibr" rid="pkd-ar.REF.shneider.2005.634">Shneider &#x00026; Magid 2005</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.telega.2013.328">Telega et al 2013</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>]</p>
            </list-item>
          </list>
        </sec>
        <sec id="pkd-ar.Agents_to_Avoid">
          <title>Agents to Avoid</title>
          <p>The following should be avoided:</p>
          <list list-type="bullet">
            <list-item>
              <p>For affected individuals with hypertension, sympathomimetic agents</p>
            </list-item>
            <list-item>
              <p>In general, unless the clinical situation warrants their use, known nephrotoxic agents including nonsteroidal anti-inflammatory drugs (NSAIDs) and aminoglycosides</p>
            </list-item>
          </list>
          <p>Potentially hepatotoxic agents (e.g., acetaminophen doses &#x0003e;30 mg/kg/day, herbal supplements, and alcohol) should be minimized.</p>
          <p>Work in cell and animal models suggests that caffeine, theophylline-like agents, and calcium channel blockers may exacerbate renal cyst formation and growth. However, this has not been rigorously studied in individuals with ARPKD or ADPKD.</p>
        </sec>
        <sec id="pkd-ar.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic older and younger sibs of a proband/in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variants in the family are known;</p>
            </list-item>
            <list-item>
              <p>High-resolution renal and hepatic ultrasonographic evaluation and monitoring of systemic blood pressure if the pathogenic variants in the family are not known.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="pkd-ar.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="pkd-ar.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Recent studies in two animal models of ARPKD suggest that tesevatinib (TSV), a unique multikinase inhibitor, markedly slows the progression of both renal cystic disease and hepatobiliary disease [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney">Sweeney et al, in press</xref>]. These data, in addition to safety data generated by Phase I-II multicenter clinical trial of TSV (also called KD-019) in ADPKD (ClinicalTrials.gov Identifier: NCT01559363) have led to an initial Phase I-II multicenter clinical trial of TSV in infants and children with ARPKD planned for late fall of 2016 or early 2017.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="pkd-ar.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="pkd-ar.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Autosomal recessive polycystic kidney disease (ARPKD) is caused by biallelic pathogenic variants in <italic toggle="yes">PKHD1</italic>.</p>
        </sec>
        <sec id="pkd-ar.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">PKHD1</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes for a pathogenic variant in <italic toggle="yes">PKHD1</italic> are asymptomatic and are not at risk of developing ARPKD.</p>
            </list-item>
            <list-item>
              <p>It is important to perform renal ultrasonography on parents of children with a clinical diagnosis of ARPKD (i.e., a diagnosis that has not been confirmed by <italic toggle="yes">PKHD1</italic> molecular genetic testing) to exclude the possibility of ADPKD (see <xref ref-type="sec" rid="pkd-ar.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of a proband has a 25% chance of inheriting both pathogenic variants and being affected, a 50% chance of inheriting a single pathogenic variant and being a carrier, and a 25% risk of inheriting neither pathogenic variant and not being a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes for a pathogenic variant in <italic toggle="yes">PKHD1</italic> are asymptomatic and are not at risk of developing ARPKD.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The offspring of an individual with ARPKD are obligate heterozygotes (carriers) for a <italic toggle="yes">PKHD1</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>The carrier frequency in the general population was estimated at 1:70 [<xref ref-type="bibr" rid="pkd-ar.REF.zerres.1998.303">Zerres et al 1998</xref>]. Therefore, the risk of ARPKD in offspring of a proband is approximately 0.7%.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of a <italic toggle="yes">PKHD1</italic> pathogenic variant.</p>
        </sec>
        <sec id="pkd-ar.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">PKHD1</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="pkd-ar.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="pkd-ar.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="pkd-ar.Prenatal_Testing_and_Preimplantat">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>High-risk pregnancies (i.e., those at 25% risk based on family history).</bold> Once the <italic toggle="yes">PKHD1</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk for ARPKD and preimplantation genetic diagnosis (PGD) are possible options.</p>
          <p>Note: A PGD protocol for couples who both carry a <italic toggle="yes">PKHD1</italic> pathogenic variant and wish to conceive children unaffected by ARPKD has been developed and successfully employed [<xref ref-type="bibr" rid="pkd-ar.REF.lau.2010.397">Lau et al 2010</xref>]. Genome amplification of single blastomeres by multiple displacement amplification (MDA), and haplotype analysis with novel short tandem repeat (STR) markers from <italic toggle="yes">PKHD1</italic> and flanking sequences are used [<xref ref-type="bibr" rid="pkd-ar.REF.lau.2010.397">Lau et al 2010</xref>]. (Note: This PGD protocol and the intragenic STR markers are available free of charge from Children's Hospital of Wisconsin [<xref ref-type="sec" rid="pkd-ar.Author_Notes">contact information</xref>].)</p>
          <p>No systematic data are available on the sensitivity and specificity of prenatal ultrasound examination in diagnosis of ARPKD in pregnancies at 25% risk.</p>
          <p>
            <bold>Low-risk pregnancies (i.e., those not known to be at increased risk but in which routine prenatal ultrasound examination reveals enlarged cystic kidneys)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Karyotype or array GH and detailed fetal ultrasonography should be performed to evaluate for the presence of a chromosomal abnormality and/or other congenital anomalies in a fetus not known to be at increased risk for ARPKD.</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing of <italic toggle="yes">PKHD1</italic> may be appropriate. Failure to detect two pathogenic variants, however, does not exclude the diagnosis of genetic polycystic kidney disease. A second <italic toggle="yes">PKHD1</italic> variant may have been missed by current testing techniques or the fetus may have ADPKD.</p>
            </list-item>
            <list-item>
              <p>Renal ultrasound examinations of both parents should be considered in all fetuses with suspected ARPKD (i.e., an ARPKD diagnosis not confirmed by <italic toggle="yes">PKHD1</italic> molecular genetic testing) to evaluate for the possibility of ADPKD.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="pkd-ar.Resources">
        <title>Resources</title>
      </sec>
      <sec id="pkd-ar.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="pkd-ar.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Notwithstanding the identification of <italic toggle="yes">PKHD1</italic> and its protein product, fibrocystin, the pathogenesis of autosomal recessive polycystic kidney disease (ARPKD) remains unclear [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner 2011</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner 2014</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>]. Reduced or absent function of fibrocystin is thought to underlie the disease pathogenesis [<xref ref-type="bibr" rid="pkd-ar.REF.hiesberger.2004.814">Hiesberger et al 2004</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.zhang.2004.2311">Zhang et al 2004</xref>]. Recent studies suggest that many PKD-related proteins are involved with function of the primary cilia, an organelle located on the apical surface of most epithelial cells including kidney tubule and biliary cells [<xref ref-type="bibr" rid="pkd-ar.REF.lina.2004.171">Lina &#x00026; Satlinb 2004</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.pazour.2004.2528">Pazour 2004</xref>]. Abnormal structure and/or function of the primary cilium leads to alterations in its mechanosensory properties, which may result in activation of downstream second messenger pathways, notably the cyclic AMP system [<xref ref-type="bibr" rid="pkd-ar.REF.nauli.2003.129">Nauli et al 2003</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.pazour.2004.2528">Pazour 2004</xref>]. These pathways are thought to activate known cystogenic processes such as cell proliferation and fluid secretion. A consistent feature of all proliferative cystic epithelia is the expression of qualitative and quantitative abnormalities of the EGFR-axis (reviewed in <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2011.675">Sweeney &#x00026; Avner [2011]</xref> and <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2014.148">Sweeney &#x00026; Avner [2014]</xref>). The molecular connection between gene defect, ciliary abnormalities, protein complex formation, and EGFR abnormalities remains speculative.</p>
          <p>Fibrocystin, along with polycystin-1 and polycystin-2 (involved in <related-object link-type="booklink" source-id="gene" document-id="pkd-ad" document-type="chapter">autosomal dominant polycystic kidney disease</related-object>) have been shown to interact at a molecular level in addition to direct interactions of the protein products. These cystoproteins exist as multimeric protein complexes at multiple sites in addition to cilia. These polycystin complexes are located on the apical cell surface, the lateral cell surface adjacent to the adherens junction, and the basal cell membrane in association with the focal adhesion kinase [<xref ref-type="bibr" rid="pkd-ar.REF.avner.2006.889">Avner &#x00026; Sweeney 2006</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2016">Sweeney et al 2016</xref>]. The integration of signaling downstream from multimeric protein complexes may link the molecular and cellular pathophysiology of ARPKD; c-Src has been identified as a key intermediate in the abnormal signaling of fibrocystin [<xref ref-type="bibr" rid="pkd-ar.REF.sweeney.2008.1331">Sweeney et al 2008</xref>; <xref ref-type="bibr" rid="pkd-ar.REF.sweeney">Sweeney et al, in press</xref>].</p>
          <p>Hypertension in ADPKD is believed to be mediated by the renin-angiotensin system (RAS); however, supporting data in ARPKD are limited. Studies in the last decade have highlighted the complexity of the RAS system and the importance of &#x0201c;local&#x0201d; (e.g., kidney-specific) RAS activation that may not be reflected in systemic measurements. The potential role of local kidney RAS in the pathogenesis of hypertension in ARPKD is supported by a histologic study that demonstrated increased expression of several renin-angiotensin axis components in two kidneys of individuals with ARPKD [<xref ref-type="bibr" rid="pkd-ar.REF.loghmanadham.2005.979">Loghman-Adham et al 2005</xref>]. More recent data in an ARPKD animal model demonstrated RAS activation in the kidneys of affected animals and also in the liver [<xref ref-type="bibr" rid="pkd-ar.REF.goto.2010a.2449">Goto et al 2010a</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.goto.2010b.639">Goto et al 2010b</xref>]. This raises the question of whether RAS activation may be a more fundamental feature of ARPKD pathogenesis rather than a nonspecific manifestation of chronic kidney disease.</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">PKHD1</italic> is an extremely large gene that comprises 86 coding exons [<xref ref-type="bibr" rid="pkd-ar.REF.onuchic.2002.1305">Onuchic et al 2002</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.ward.2002.259">Ward et al 2002</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.bergmann.2004.453">Bergmann et al 2004</xref>]. The largest reading frame encompasses 67 exons (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_138694.3">NM_138694.3</ext-link>), but multiple alternatively spliced transcripts have been described [<xref ref-type="bibr" rid="pkd-ar.REF.bergmann.2004.453">Bergmann et al 2004</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="pkd-ar" object-id="pkd-ar.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic variants.</bold> Different types of variants are distributed across the gene. See LSDB and HGMD Databases in <related-object source-id="gene" document-id="pkd-ar" object-id="pkd-ar.molgen.TA">Table A</related-object>.</p>
          <p><bold>Normal gene product.</bold> The <italic toggle="yes">PKHD1</italic> product is a large protein with receptor-like properties [<xref ref-type="bibr" rid="pkd-ar.REF.onuchic.2002.1305">Onuchic et al 2002</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.ward.2002.259">Ward et al 2002</xref>]. It is localized to kidney, bile ducts, and pancreas. In addition, fibrocystin has been shown to localize to primary cilia as well as other discrete locations in renal tubular epithelial cells, suggesting a possible link of multiple pathways to ciliary dysfunction in some instances [<xref ref-type="bibr" rid="pkd-ar.REF.ward.2003.2703">Ward et al 2003</xref>], or multimeric protein complex signaling in cystic epithelium and endothelium. Abnormalities in ciliary structure and function may participate in the pathogenesis of many different types of cystic kidney diseases [<xref ref-type="bibr" rid="pkd-ar.REF.ong.2003.774">Ong &#x00026; Wheatley 2003</xref>] (see <xref ref-type="sec" rid="pkd-ar.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>).</p>
          <p><bold>Abnormal gene product.</bold> Reduced or absent function of fibrocystin is thought to underlie the disease pathogenesis [<xref ref-type="bibr" rid="pkd-ar.REF.hiesberger.2004.814">Hiesberger et al 2004</xref>, <xref ref-type="bibr" rid="pkd-ar.REF.zhang.2004.2311">Zhang et al 2004</xref>]. See <xref ref-type="sec" rid="pkd-ar.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>.</p>
        </sec>
      </sec>
      <sec id="pkd-ar.References">
        <title>References</title>
        <sec id="pkd-ar.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="pkd-ar.Literature_Cited.reflist0">
            <ref id="pkd-ar.REF.adeva.2006.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Adeva</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Youssef</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamath</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubly</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Consugar</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>BF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>VE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>PC</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD).</article-title>
                <source>Medicine (Baltimore)</source>
                <volume>85</volume>
                <fpage>1</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">16523049</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.avner.2006.889">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Avner</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweeney</surname>
                    <given-names>WE</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Renal cystic disease: new insights for the clinician.</article-title>
                <source>Pediatr Clin North Am</source>
                <volume>53</volume>
                <fpage>889</fpage>
                <lpage>909</lpage>
                <pub-id pub-id-type="pmid">17027616</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.bergmann.2004.453">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bergmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Senderek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000fc;pper</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dornia</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Windelen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eggermann</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudnik-Sch&#x000f6;neborn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirfel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onuchic</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somlo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guay-Woodford</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germino</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000fc;ttner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zerres</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD).</article-title>
                <source>Hum Mutat.</source>
                <year>2004</year>
                <volume>23</volume>
                <fpage>453</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">15108277</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.bergmann.2005.829">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bergmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Senderek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Windelen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000fc;pper</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Middeldorf</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dornia</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudnik-Sch&#x000f6;neborn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konrad</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seeman</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neuhaus</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vester</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirfel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000fc;ttner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zerres</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>APN (Arbeitsgemeinschaft f&#x000fc;r P&#x000e4;diatrische Nephrologie). Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD).</article-title>
                <source>Kidney Int.</source>
                <year>2005</year>
                <volume>67</volume>
                <fpage>829</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">15698423</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.blyth.1971.257">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blyth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ockenden</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>1971</year>
                <article-title>Polycystic disease of kidney and liver presenting in childhood.</article-title>
                <source>J Med Genet</source>
                <volume>8</volume>
                <fpage>257</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">5097134</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.bockenhauer.2016.707">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bockenhauer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaureguiberry</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>HNF1B-associated clinical phenotypes: the kidney and beyond.</article-title>
                <source>Pediatr Nephrol.</source>
                <volume>31</volume>
                <fpage>707</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">26160100</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.brinkert.2013.640">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brinkert</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehnhardt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montoya</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Helmke</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nashan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganschow</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemper</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Combined liver-kidney transplantation for children with autosomal recessive polycystic kidney disease (ARPKD): indication and outcome.</article-title>
                <source>Transpl Int.</source>
                <volume>26</volume>
                <fpage>640</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">23582048</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.chalhoub.2013.114">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chalhoub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abi-Rafeh</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hachem</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayoub</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yazbeck</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Intracranial aneurysm and recessive polycystic kidney disease: the third reported case.</article-title>
                <source>JAMA Neurol.</source>
                <year>2013</year>
                <volume>70</volume>
                <fpage>114</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">23318517</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.chandar.2015.1233">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chandar</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jorge</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tekin</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Transplantation in autosomal recessive polycystic kidney disease: liver and/or kidney?</article-title>
                <source>Pediatr Nephrol.</source>
                <volume>30</volume>
                <fpage>1233</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">25115876</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.chapal.2012.2083">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chapal</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Debout</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dufay</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roussey</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burtey</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Launay</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vigneau</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blancho</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loirat</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hourmant</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fakhouri</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Kidney and liver transplantation in patients with autosomal recessive polycystic kidney disease: a multicentric study.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <year>2012</year>
                <volume>27</volume>
                <fpage>2083</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22076432</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.clissold.2015.102">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clissold</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamilton</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattersley</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bingham</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>HNF1B-associated renal and extra-renal disease -- an expanding clinical spectrum.</article-title>
                <source>Nat Rev Nephrol.</source>
                <volume>11</volume>
                <fpage>102</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">25536396</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.committee_on_infectious_diseases.2009.1694">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>Committee on Infectious Diseases</collab>
                </person-group>
                <year>2009</year>
                <article-title>From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.</article-title>
                <source>Pediatrics.</source>
                <volume>124</volume>
                <fpage>1694</fpage>
                <lpage>701</lpage>
                <pub-id pub-id-type="pmid">19736258</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.dell.2009">
              <mixed-citation publication-type="book">Dell KM, Sweeney WE, Avner ED. Polycystic kidney disease. In: Avner ED, Harmon W, Niadet P, Yoshikawa N, eds. <italic toggle="yes">Pediatric Nephrology</italic>. 6 ed. Heidelberg, Germany: Springer-Verlag; 2009:849-88.</mixed-citation>
            </ref>
            <ref id="pkd-ar.REF.fick.1993.1863">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fick</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strain</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimberling</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manco-Johnson</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duley</surname>
                    <given-names>IT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabow</surname>
                    <given-names>PA</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>Characteristics of very early onset autosomal dominant polycystic kidney disease.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>3</volume>
                <fpage>1863</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">8338917</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.fonck.2001.1648">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fonck</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chauveau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gagnadoux</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirson</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gr&#x000fc;nfeld</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Autosomal recessive polycystic kidney disease in adulthood.</article-title>
                <source>Nephrol Dial Transplant</source>
                <volume>16</volume>
                <fpage>1648</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">11477168</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.frank.2014.1729">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Frank</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zerres</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergmann</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Transcriptional complexity in autosomal recessive polycystic kidney disease.</article-title>
                <source>Clin J Am Soc Nephrol.</source>
                <volume>9</volume>
                <fpage>1729</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">25104275</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.goto.2010a.2449">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoxha</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dell</surname>
                    <given-names>KM</given-names>
                  </name>
                </person-group>
                <year>2010a</year>
                <article-title>The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>25</volume>
                <fpage>2449</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">20798958</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.goto.2010b.639">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoxha</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wells</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dell</surname>
                    <given-names>KM</given-names>
                  </name>
                </person-group>
                <year>2010b</year>
                <article-title>Renin-angiotensin system (RAS) activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease (ARPKD).</article-title>
                <source>J Pediatr Gastroenterol Nutr</source>
                <volume>50</volume>
                <fpage>639</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">20400910</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.guaywoodford.2014.611">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guay-Woodford</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bissler</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braun</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bockenhauer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cadnapaphornchai</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dell</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerecuk</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liebau</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alonso-Peclet</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shneider</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emre</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heller</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamath</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murray</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moise</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eichenwald</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keller</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilkins-Haug</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gunay-Aygun</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hooper</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartung</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Streisand</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrone</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moxey-Mims</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference.</article-title>
                <source>J Pediatr.</source>
                <volume>165</volume>
                <fpage>611</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">25015577</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.guaywoodford.2003.1072">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guay-Woodford</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desmond</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Autosomal recessive polycystic kidney disease: the clinical experience in North America.</article-title>
                <source>Pediatrics.</source>
                <year>2003</year>
                <volume>111</volume>
                <fpage>1072</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">12728091</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.guaywoodford.1998.173">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guay-Woodford</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galliani</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Musulman-Mroczek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spear</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guillot</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernstein</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Diffuse renal cystic disease in children: morphologic and genetic correlations.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>12</volume>
                <fpage>173</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">9630032</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.gunayaygun.2013.112">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gunay-Aygun</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Font-Montgomery</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukose</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuchman Gerstein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piwnica-Worms</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choyke</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daryanani</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turkbey</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sincan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandler</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roque</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Douek</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graf</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huizing</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heller</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease.</article-title>
                <source>Gastroenterology.</source>
                <year>2013</year>
                <volume>144</volume>
                <fpage>112</fpage>
                <lpage>121.e2</lpage>
                <pub-id pub-id-type="pmid">23041322</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.gunayaygun.2010b.972">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gunay-Aygun</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Font-Montgomery</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukose</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuchman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graf</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleta</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piwnica-Worms</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krasnewich</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oden</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ling</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quezado</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zak</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daryanani</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turkbey</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choyke</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guay-Woodford</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                </person-group>
                <year>2010b</year>
                <article-title>Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease.</article-title>
                <source>Clin J Am Soc Nephrol</source>
                <volume>5</volume>
                <fpage>972</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">20413436</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.gunayaygun.2010a.160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gunay-Aygun</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuchman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Font-Montgomery</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukose</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ausavarat</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piwnica-Worms</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huizing</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guay-Woodford</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                </person-group>
                <year>2010a</year>
                <article-title>PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis.</article-title>
                <source>Mol Genet Metab</source>
                <volume>99</volume>
                <fpage>160</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">19914852</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.harps.2011.1127">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harps</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brinkert</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganschow</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briem-Richter</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Husen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidtke</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herden</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nashan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemper</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Immediate postoperative intensive care treatment of pediatric combined liver-kidney transplantation: outcome and prognostic factors.</article-title>
                <source>Transplantation</source>
                <volume>91</volume>
                <fpage>1127</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">21544033</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.hartung.2014.e833">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hartung</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guay-Woodford</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects.</article-title>
                <source>Pediatrics.</source>
                <volume>134</volume>
                <fpage>e833</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">25113295</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.hartung.2014.1957">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hartung</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matheson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lande</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dell</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guay-Woodford</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerson</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warady</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hooper</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furth</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Neurocognition in children with autosomal recessive polycystic kidney disease in the CKiD cohort study.</article-title>
                <source>Pediatr Nephrol.</source>
                <volume>29</volume>
                <fpage>1957</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">24828609</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.hiesberger.2004.814">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hiesberger</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bai</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McNally</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinclair</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tian</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somlo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Igarashi</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mutation of hepatocyte nuclear factor-1beta inhibits Pkhd1 gene expression and produces renal cysts in mice.</article-title>
                <source>J Clin Invest</source>
                <volume>113</volume>
                <fpage>814</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">15067314</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.hoyer.2015.186">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoyer</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Clinical manifestations of autosomal recessive polycystic kidney disease.</article-title>
                <source>Curr Opin Pediatr.</source>
                <volume>27</volume>
                <fpage>186</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">25689455</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.jahnukainen.2015.944">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jahnukainen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirjavainen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ylinen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linkosalo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arikoski</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pakarinen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jalanko</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2015</year>
                <article-title>Long-term pulmonary function in children with recessive polycystic kidney disease.</article-title>
                <source>Arch Dis Child.</source>
                <volume>100</volume>
                <fpage>944</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">26163120</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.johnson.2003.311">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gissen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sergi</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Molecular pathology and genetics of congenital hepatorenal fibrocystic syndromes.</article-title>
                <source>J Med Genet</source>
                <volume>40</volume>
                <fpage>311</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12746391</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.kamath.2003.857">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kamath</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piccoli</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Heritable disorders of the bile ducts.</article-title>
                <source>Gastroenterol Clin North Am</source>
                <volume>32</volume>
                <fpage>857</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">14562578</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.kaplan.1988.639">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Chadarevian</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jequier</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Regan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1988</year>
                <article-title>Variable expression of autosomal recessive polycystic kidney disease and congenital hepatic fibrosis within a family.</article-title>
                <source>Am J Med Genet</source>
                <volume>29</volume>
                <fpage>639</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">3377007</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.lau.2010.397">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lau</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janson</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roesler</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avner</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strawn</surname>
                    <given-names>EY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bick</surname>
                    <given-names>DP</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Birth of a healthy infant following preimplantation PKHD1 haplotyping for autosomal recessive polycystic kidney disease using multiple displacement amplification.</article-title>
                <source>J Assist Reprod Genet</source>
                <volume>27</volume>
                <fpage>397</fpage>
                <lpage>407</lpage>
                <pub-id pub-id-type="pmid">20490649</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.lilova.2003.57">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lilova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyers</surname>
                    <given-names>KE</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Recombinant human growth hormone therapy in autosomal recessive polycystic kidney disease.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>18</volume>
                <fpage>57</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">12488992</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.limwongse.2016">
              <mixed-citation publication-type="book">Limwongse C. Developmental syndromes and malformations of the urinary tract. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, Francesco E, Goldstein S, eds. <italic toggle="yes">Pediatric Nephrology.</italic> 7 ed. Springer. 2016:135-78.</mixed-citation>
            </ref>
            <ref id="pkd-ar.REF.limwongse.1999">
              <mixed-citation publication-type="book">Limwongse C, Clarren SK, Cassidy SB. Syndromes and malformations of the urinary tract. In: Barratt TM, Avner ED, Harmon WE, eds. <italic toggle="yes">Pediatric Nephrology.</italic> 4 ed. Baltimore, MD: Lippincott Williams &#x00026; Wilkins. 1999:427-52.</mixed-citation>
            </ref>
            <ref id="pkd-ar.REF.lina.2004.171">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lina</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Satlinb</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <article-title>Polycystic kidney disease: the cilium as a common pathway in cystogenesis.</article-title>
                <source>Curr Opin Pediatr.</source>
                <year>2004</year>
                <volume>16</volume>
                <fpage>171</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15021197</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.loghmanadham.2005.979">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Loghman-Adham</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soto</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inagami</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sotelo-Avila</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Expression of components of the renin-angiotensin system in autosomal recessive polycystic kidney disease.</article-title>
                <source>J Histochem Cytochem</source>
                <volume>53</volume>
                <fpage>979</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">15879580</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.melchionda.2016.811">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Melchionda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palladino</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castellana</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giordano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benetti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Bonis</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zelante</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bisceglia</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Expanding the mutation spectrum in 130 probands with ARPKD: identification of 62 novel PKHD1 mutations by sanger sequencing and MLPA analysis.</article-title>
                <source>J Hum Genet.</source>
                <year>2016</year>
                <volume>61</volume>
                <fpage>811</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">27225849</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.nauli.2003.129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nauli</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alenghat</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luo</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vassilev</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elia</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinn</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingber</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells.</article-title>
                <source>Nat Genet</source>
                <volume>33</volume>
                <fpage>129</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">12514735</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.obrien.2012.83">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>O'Brien</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Font-Montgomery</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukose</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piwnica-Worms</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riney</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daryanani</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choyke</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heller</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gunay-Aygun</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease.</article-title>
                <source>J Pediatr Gastroenterol Nutr.</source>
                <volume>54</volume>
                <fpage>83</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21694639</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.ong.2003.774">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ong</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wheatley</surname>
                    <given-names>DN</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Polycystic kidney disease--the ciliary connection.</article-title>
                <source>Lancet</source>
                <volume>361</volume>
                <fpage>774</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12620752</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.onuchic.2002.1305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Onuchic</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagasawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hou</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eggermann</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ren</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Senderek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esquivel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeltner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudnik-Sch&#x000f6;neborn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mrug</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweeney</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avner</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zerres</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guay-Woodford</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somlo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germino</surname>
                    <given-names>GG</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin- transcription-factor domains and parallel beta-helix 1 repeats.</article-title>
                <source>Am J Hum Genet</source>
                <volume>70</volume>
                <fpage>1305</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">11898128</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.pazour.2004.2528">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pazour</surname>
                    <given-names>GJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>15</volume>
                <fpage>2528</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">15466257</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.pei.2009.205">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pei</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obaji</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupuis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paterson</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magistroni</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dicks</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parfrey</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cramer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coto</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torra</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>San Millan</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breuning</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ravine</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Unified criteria for ultrasonographic diagnosis of ADPKD.</article-title>
                <source>J Am Soc Nephrol.</source>
                <year>2009</year>
                <volume>20</volume>
                <fpage>205</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">18945943</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.roy.1997.302">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dillon</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trompeter</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barratt</surname>
                    <given-names>TM</given-names>
                  </name>
                </person-group>
                <article-title>Autosomal recessive polycystic kidney disease: long-term outcome of neonatal survivors.</article-title>
                <source>Pediatr Nephrol.</source>
                <year>1997</year>
                <volume>11</volume>
                <fpage>302</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9203177</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.schaeffer.2016">
              <mixed-citation publication-type="book">Schaeffer F. Endocrine and growth abnormallities in chronic kidney disease. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, Francesco E, Goldstein S, eds. <italic toggle="yes">Pediatric Nephrology.</italic> 7 ed. Springer. 2016:2295-348.</mixed-citation>
            </ref>
            <ref id="pkd-ar.REF.seikaly.2007.1195">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seikaly</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salhab</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warady</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stablein</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Use of rhGH in children with chronic kidney disease: lessons from NAPRTCS.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>22</volume>
                <fpage>1195</fpage>
                <lpage>204</lpage>
                <pub-id pub-id-type="pmid">17530299</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.sharp.1997.77">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sharp</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergman</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockwin</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robbin</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galliani</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guay-Woodford</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Dominantly transmitted glomerulocystic kidney disease: a distinct genetic entity.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>8</volume>
                <fpage>77</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">9013451</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.shneider.2005.634">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shneider</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magid</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Liver disease in autosomal recessive polycystic kidney disease.</article-title>
                <source>Pediatr Transplant</source>
                <volume>9</volume>
                <fpage>634</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16176423</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.shukla.2004.2000">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shukla</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiddoo</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canning</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Unilateral nephrectomy as palliative therapy in an infant with autosomal recessive polycystic kidney disease.</article-title>
                <source>J Urol</source>
                <volume>172</volume>
                <fpage>2000</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">15540776</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.sweeney.2016">
              <mixed-citation publication-type="book">Sweeney W Jr, Gunay-Aygun M, Patil A, Avner ED. Childhood polycystic kidney disease. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, Francesco E, Goldstein S, eds. <italic toggle="yes">Pediatric Nephrology.</italic> 7 ed. Springer. 2016:1103-53.</mixed-citation>
            </ref>
            <ref id="pkd-ar.REF.sweeney.2011.675">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sweeney</surname>
                    <given-names>WE</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Avner</surname>
                    <given-names>ED</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Diagnosis and management of childhood polycystic kidney disease.</article-title>
                <source>Pediatr Nephrol</source>
                <volume>26</volume>
                <fpage>675</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">21046169</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.sweeney.2014.148">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sweeney</surname>
                    <given-names>WE</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Avner</surname>
                    <given-names>ED</given-names>
                  </name>
                </person-group>
                <article-title>Pathophysiology of childhood polycystic kidney diseases: new insights into disease-specific therapy.</article-title>
                <source>Pediatr Res.</source>
                <year>2014</year>
                <volume>75</volume>
                <fpage>148</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">24336431</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.sweeney.2008.1331">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sweeney</surname>
                    <given-names>WE</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>von Vigier</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frost</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avner</surname>
                    <given-names>ED</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Src Inhibition ameliorates polycystic kidney disease.</article-title>
                <source>J Am Soc Nephrol</source>
                <volume>19</volume>
                <fpage>1331</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">18385429</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.sweeney">
              <mixed-citation publication-type="other">Sweeney WE, Frost P, Avner ED. Tesevatinib ameliorates progression of ARPKD in rodent models. In press</mixed-citation>
            </ref>
            <ref id="pkd-ar.REF.telega.2013.328">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Telega</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cronin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avner</surname>
                    <given-names>ED</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>New approaches to the autosomal recessive polycystic kidney disease patient with dual kidney-liver complications.</article-title>
                <source>Pediatr Transplant.</source>
                <volume>17</volume>
                <fpage>328</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">23593929</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.tsimaratos.2000.856">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsimaratos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cloarec</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roquelaure</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Retornaz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picon</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabrol</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guys</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarles</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nivet</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Chronic renal failure and portal hypertension--is portosystemic shunt indicated?</article-title>
                <source>Pediatr Nephrol</source>
                <volume>14</volume>
                <fpage>856</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10955945</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.turkbey.2009.100">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Turkbey</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ocak</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daryanani</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Font-Montgomery</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukose</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuchman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heller</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choyke</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gunay-Aygun</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF).</article-title>
                <source>Pediatr Radiol.</source>
                <volume>39</volume>
                <fpage>100</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">19089418</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.verhave.2016.345">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verhave</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bech</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wetzels</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nijenhuis</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>hepatocyte nuclear factor 1beta-associated kidney disease: more than renal cysts and diabetes.</article-title>
                <source>J Am Soc Nephrol.</source>
                <volume>27</volume>
                <fpage>345</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">26319241</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.ward.2002.259">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hogan</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossetti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sneddon</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubly</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunningham</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacallao</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishibashi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milliner</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>VE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>PC</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein.</article-title>
                <source>Nat Genet</source>
                <volume>30</volume>
                <fpage>259</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">11919560</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.ward.2003.2703">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masyuk</surname>
                    <given-names>TV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Punyashthiti</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whelan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacallao</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torra</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LaRusso</surname>
                    <given-names>NF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>VE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>PC</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia.</article-title>
                <source>Hum Mol Genet</source>
                <volume>12</volume>
                <fpage>2703</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">12925574</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.watkins.1999">
              <mixed-citation publication-type="book">Watkins SL, McDonald RA, Avner ED. Renal dysplasia, hypoplasia and miscellaneous cystic disorders. In: Barratt TM, Avner ED, Harmon WE, eds. <italic toggle="yes">Pediatric Nephrology.</italic> 4 ed. Baltimore, MD: Lippincott Williams &#x00026; Wilkins. 1999:415-25.</mixed-citation>
            </ref>
            <ref id="pkd-ar.REF.wen.2011.460">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wen</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease.</article-title>
                <source>Clin Transl Sci.</source>
                <year>2011</year>
                <volume>4</volume>
                <fpage>460</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">22212229</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.zerres.1996.437">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zerres</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudnik-Sch&#x000f6;neborn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deget</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holtkamp</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brodehl</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geisert</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scharer</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft f&#x000fc; P&#x000e4;diatrische, Nephrologie.</article-title>
                <source>Acta Paediatr</source>
                <volume>85</volume>
                <fpage>437</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">8740301</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.zerres.1998.303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zerres</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudnik-Sch&#x000f6;neborn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinkamm</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mucher</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Autosomal recessive polycystic kidney disease.</article-title>
                <source>J Mol Med</source>
                <volume>76</volume>
                <fpage>303</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9587064</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.zhang.2004.2311">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>MZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mai</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cho</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hao</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moeckel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiong</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakanuma</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lilova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pei</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coffey</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>XZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breyer</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>ZJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKanna</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <volume>101</volume>
                <fpage>2311</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">14983006</pub-id>
              </element-citation>
            </ref>
            <ref id="pkd-ar.REF.zvereff.2010.505">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zvereff</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yao</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsey</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mikhail</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vijzelaar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messiaen</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Identification of PKHD1 multiexon deletions using multiplex ligation-dependent probe amplification and quantitative polymerase chain reaction.</article-title>
                <source>Genet Test Mol Biomarkers</source>
                <volume>14</volume>
                <fpage>505</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">20575693</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="pkd-ar.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="pkd-ar.Suggested_Reading.reflist0">
            <ref id="pkd-ar.REF.harris.2009.1188">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>PC</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>2008 Homer W. Smith Award: insights into the pathogenesis of polycystic kidney disease from gene discovery.</article-title>
                <source>J Am Soc Nephrol.</source>
                <volume>20</volume>
                <fpage>1188</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">19423684</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="pkd-ar.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="pkd-ar.Author_Notes">
          <title>Author Notes</title>
          <p>
            <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.chw.org/research">Children's Research Institute Web site</ext-link>
          </p>
          <p>Contact information for Children's Hospital of Wisconsin (preimplantation genetic diagnosis protocol)</p>
          <p>Estil Y Strawn MDSection Chief, Department of, Obstetrics and GynecologyMedical College of WisconsinFroedert Hospital900 W Wisconsin AveMilwaukee WI 53226414-805-3666estrawn@mcw.edu</p>
        </sec>
        <sec id="pkd-ar.Author_History">
          <title>Author History</title>
          <p>Ellis D Avner, MD (2001-present)Katherine MacRae Dell, MD; Case Western Reserve University School of Medicine (2001-2014)William E Sweeney, MS (2014-present)</p>
        </sec>
        <sec id="pkd-ar.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>15 September 2016 (ha) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>6 March 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>22 September 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>14 July 2009 (cd) Revision: deletion/duplication analysis available clinically</p>
            </list-item>
            <list-item>
              <p>7 August 2008 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 March 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>23 October 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>13 January 2003 (kmd) Revision: gene identified</p>
            </list-item>
            <list-item>
              <p>19 July 2001 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>April 2001 (kmd) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="pkd-ar.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>New approaches to the individual with autosomal recessive polycystic kidney disease who has dual kidney&#x02013;liver complications.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pkd-ar-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
